Search hospitals > Louisiana > Marrero
Tandem Clinical Research
Claim this profileMarrero, Louisiana 70072
Global Leader in Non-alcoholic Fatty Liver Disease
Global Leader in Fatty Liver
Conducts research for Fatty Liver Disease
Conducts research for Liver Fibrosis
Conducts research for Liver Disease
99 reported clinical trials
4 medical researchers
Summary
Tandem Clinical Research is a medical facility located in Marrero, Louisiana. This center is recognized for care of Non-alcoholic Fatty Liver Disease, Fatty Liver, Fatty Liver Disease, Liver Fibrosis, Liver Disease and other specialties. Tandem Clinical Research is involved with conducting 99 clinical trials across 117 conditions. There are 4 research doctors associated with this hospital, such as Gary Reiss, MD, Adil Fatakia, MD, Lincoln Hernandez, MD, and Angela Traylor, MD.Area of expertise
1Non-alcoholic Fatty Liver Disease
Global LeaderStage I
Stage II
2Fatty Liver
Global LeaderStage I
Stage II
Top PIs
Gary Reiss, MDTandem Clinical Research4 years of reported clinical research
Studies Non-alcoholic Fatty Liver Disease
Studies Fatty Liver
20 reported clinical trials
21 drugs studied
Adil Fatakia, MDTandem Clinical Research4 years of reported clinical research
Studies Obesity
Studies Type 2 Diabetes
14 reported clinical trials
22 drugs studied
Lincoln Hernandez, MDTandem Clinical Research, LLC4 years of reported clinical research
Studies Non-alcoholic Fatty Liver Disease
Studies Fatty Liver
3 reported clinical trials
6 drugs studied
Angela Traylor, MDTandem Clinical Research, Marrero2 years of reported clinical research
Studies Dementia
Studies Lewy Body Dementia
1 reported clinical trial
1 drug studied
Clinical Trials running at Tandem Clinical Research
Fatty Liver
Liver Fibrosis
Ulcerative Colitis
Type 2 Diabetes
Major Depressive Disorder
Thyroid Fibrosis
Stenosis
Healthy Subjects
Ascites
Fatty Liver Disease
Survodutide
for Fatty Liver Disease
This study is open to adults who are at least 18 years old and have: * a confirmed liver disease called non-alcoholic steatohepatitis (NASH)/metabolic-associated steatohepatitis (MASH) and * moderate or advanced liver fibrosis People with a history of acute or chronic liver diseases other than MASH or chronic alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function. This study has 2 parts. The purpose of the first part of this study is to find out the effect of survodutide on MASH and liver fibrosis. The purpose of the second part is to find out how safe and effective survodutide is in improving liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. The survodutide doses are slowly increased until the target dose is reached. All participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for up to 7 years. During this time, they regularly visit the study site or have remote visits by video call. For about the first year of the study, participants have these visits every 2 weeks, increasing to every 4 weeks and then every 6 weeks. After being in the study for a little over a year participants will then alternate between visiting the study site or having a remote visit every 3 months until the end of the study. The doctors check participants' health and take note of any unwanted effects. The participants' body weight and effects on the stomach and intestines are regularly measured. At some visits the liver is measured using different imaging methods. At 2 or 3 visits doctors take a small sample of liver tissue (biopsy). The participants also fill in questionnaires about their symptoms and quality of life. The results are compared between the groups to see whether the treatment works.
Recruiting1 award Phase 31 criteria
Survodutide
for Fatty Liver Disease
This study is open to adults who are at least 18 years old and have: * A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or * A confirmed liver disease called metabolic-associated steatohepatitis (MASH) * BMI of 27 kg/m2 or more or * 25 kg/m2 or more if the participant is Asian. People with a history of other chronic liver diseases or high alcohol intake cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people with NASH or MASH improve their liver function. Participants are put into 2 groups randomly, which means by chance. 1 group gets survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Each participant has twice the chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week. All participants regularly receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for up to 4 and a half years. During this time, they visit the study site or have a remote visit by video call every 2, 4 or 6 weeks for about a 1 year and 5 months. After this time participants visit the trial site or have a remote visit every 3 months until the end of the study. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At some visits the liver parameters are measured using different imaging methods. The participants also fill in questionnaires about their symptoms. The results are compared between the groups to see whether the treatment works.
Recruiting1 award Phase 32 criteria
ALN-HSD
for NASH with Fibrosis
This trial is testing a new drug called ALN-HSD to help people with a liver disease called NASH. NASH causes fat to build up in the liver, leading to damage and scarring. The drug aims to reduce this damage and improve liver health.
Recruiting0 awards Phase 22 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Tandem Clinical Research?
Tandem Clinical Research is a medical facility located in Marrero, Louisiana. This center is recognized for care of Non-alcoholic Fatty Liver Disease, Fatty Liver, Fatty Liver Disease, Liver Fibrosis, Liver Disease and other specialties. Tandem Clinical Research is involved with conducting 99 clinical trials across 117 conditions. There are 4 research doctors associated with this hospital, such as Gary Reiss, MD, Adil Fatakia, MD, Lincoln Hernandez, MD, and Angela Traylor, MD.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.